Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Relay Therapeutics, Inc. (RLAY : NSDQ)

• Company Description    Relay Therapeutics Inc. is a clinical-stage precision medicines company. It focuses on enhancing small molecule therapeutic discovery in targeted oncology. The company's product pipeline consist RLY-1971, RLY-4008 and RLY-PI3K1047 which are in clinical stage. Relay Therapeutics Inc. is based in Cambridge, Massachusetts. Number of Employees: 192

• Price / Volume Information    Yesterday's Closing Price: $13.53 Daily Weekly Monthly 20 Day Moving Average: 4,359,833 shares Shares Outstanding: 191.59 (millions) Market Capitalization: $2,592.16 (millions) Beta: 1.74 52 Week High: $17.32 52 Week Low: $2.75 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -10.34% -14.72% 12 Week 47.71% 36.55% Year To Date 59.93% 48.45%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 60 HAMPSHIRE STREET - CAMBRIDGE,MA 02139 USA ph: 617-370-8837 fax: - investors@relaytx.com http://www.relaytx.com

• General Corporate Information    Officers Sanjiv K. Patel - Chief Executive Officer President and Director Thomas Catinazzo - Chief Financial Officer Alexis Borisy - Director Linda A. Hill - Director Douglas S. Ingram - Director Peer Information Relay Therapeutics, Inc. (GSAC) Relay Therapeutics, Inc. (CASIF) Relay Therapeutics, Inc. (ALCD.) Relay Therapeutics, Inc. (OMNN) Relay Therapeutics, Inc. (CGPI.) Relay Therapeutics, Inc. (CATX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 75943R102 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/06/26 Share - Related Items Shares Outstanding: 191.59 Most Recent Split Date: (:1) Beta: 1.74 Market Capitalization: $2,592.16 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.42 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.59 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 6.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/06/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 4.04 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 10.87% vs. Previous Quarter: -28.13% Sales Growth vs. Year Ago Period: -60.93% vs. Previous Quarter: -57.14% ROE 03/31/26 - -43.94 12/31/25 - -43.17 09/30/25 - -42.94 ROA 03/31/26 - -40.11 12/31/25 - -39.22 09/30/25 - -38.78 Current Ratio 03/31/26 - 22.13 12/31/25 - 22.61 09/30/25 - 19.14 Quick Ratio 03/31/26 - 22.13 12/31/25 - 22.61 09/30/25 - 19.14 Operating Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Net Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Pre-Tax Margin 03/31/26 - -2,554.14 12/31/25 - -1,800.58 09/30/25 - -3,561.43 Book Value 03/31/26 - 3.35 12/31/25 - 3.27 09/30/25 - 3.52 Inventory Turnover 03/31/26 - - 12/31/25 - - 09/30/25 - - Debt-to-Equity 03/31/26 - 0.00 12/31/25 - 0.00 09/30/25 - 0.00 Debt-to-Capital 03/31/26 - 0.00 12/31/25 - 0.00 09/30/25 - 0.00

Powered by Zacks Investment Research ©